公开(公告)号：DE2431734A1

公开(公告)日：1976-01-29

申请号：DE2431734

申请日：1974-07-02

Applicant: BASF AG

Inventor： STACHEL HANS-DIETRICH PROF DR ,  DRASCH GUSTAV DR ,  KUNZE JOHANNES DR ,  PEH JUTTA DR

IPC: C07D275/02 ,  C07D275/03 ,  C07D327/04 ,  A61K31/39 ,  A61K31/425

Abstract: Beta-Keto propane sultones and sultams of formula (I), and their enol ether and enamine derivs., are new: (where R1 is H or 1-6C alkyl and R2 is H, 1-6C alkyl or 7-10C aralkyl, or CR1R2 forms a 5-7C cycloaliphatic gp.; R3 is H, 1-4C alkyl or 3-6C alkenyl (both opt. substd. by amino, phenyl or a heterocyclic gp.), alkoxycarbonyl, aliphatic or aromatic carboxylic acyl, or phenyl and R4 is H, or R3+R4 forms opt. substd. alkylidene or benzylidene; X is O or NR; R is H, lower alkyl or phenyl). Cpds. (I) and their enol ethers and enamines inhibit immune reactions and can be used to treat autoimmune disorders and esp. for inhibiting transplant rejection. Specif. claimed is 5,5-dimethyl-4-methoxy-5H-1,2-oxathiole 2,2-dioxide (Ia).

公开(公告)号：DE2966809D1

公开(公告)日：1984-04-19

申请号：DE2966809

申请日：1979-12-06

Applicant: BASF AG

Inventor： THYES MARCO DR DIPL CHEM ,  GRIES JOSEF DR ,  LEHMANN HANS DIETER DR ,  LENKE DIETER DR ,  KUNZE JOHANNES DR

IPC: A61K31/50 ,  A61K31/395 ,  A61K31/502 ,  A61P7/02 ,  A61P9/12 ,  C07C62/38 ,  C07C205/56 ,  C07D231/54 ,  C07D237/26

Abstract: 2-Aryl-3,4-diaza-bicyclo-[4.1.0]hept-2-en-5-ones, substituted in the phenyl ring, of the general formula their preparation, and therapeutic agents, containing these compounds, which may be used for the treatment of hypertension or of thrombo-embolic disorders.

公开(公告)号：DE2861089D1

公开(公告)日：1981-12-03

申请号：DE2861089

申请日：1978-06-01

Applicant: BASF AG

Inventor： LEBKUECHER ROLF DR ,  THYES MARCO DR ,  KOENIG HORST DR ,  LEHMANN HANS DIETER DR ,  GRIES JOSEF DR ,  LENKE DIETER DR ,  KUNZE JOHANNES DR

IPC: C07D237/00 ,  A61K31/50 ,  A61P7/02 ,  A61P9/12 ,  C07D237/04

Abstract: 6-(p-Acylaminophenyl)-4,5-dihydropyridaz-3-ones of the formula I I where R1 is hydrogen or alkyl of 1 to 3 carbon atoms and R2, if R1 is hydrogen, is halogen-substituted alkyl of 3 to 6 carbon atoms or beta -haloethyl or, if R1 is alkyl of 1 to 3 carbon atoms, is halogen-substituted alkyl of 1 to 6 carbon atoms, their manufacture, and therapeutic agents which contain, as the active ingredient, a compound of the formula I, where R2 may also be halomethyl or alpha -haloethyl if R1 is hydrogen. These compounds may be used as anti-hypertensive agents and for the prophylaxis and therapy of thromboembolic disorders.